Clinical Trials Logo

Clinical Trial Summary

The lockdown consequent to Coronavirus outbreak has had a differential impact on the drinking behaviour on the general population. The impact is unknown on the people with underlying chronic liver disease related to alcohol as some of them may have complex psychosocial background. The alcohol consumption in people with Alcohol-related Liver Disease (ArLD) is either due to alcohol dependence or related to their lifestyle. Alcohol dependence is a chronic relapsing remitting condition and this is associated with 60% mortality at 5 years in people who continue drinking. Recovery from alcohol-use disorder (AUD) has been made more difficult during lock-down because peer support meetings such as Alcoholics Anonymous (AA) have no longer been taking place; a majority of the residential rehabilitation centres have closed or are no longer accepting admissions (PHE, 2020) and the single detoxification unit in London has been requisitioned as a COVID-19 step-down facility. The aim of the study is to understand the influence of lockdown on the craving of alcohol and severity of alcohol dependence in patients with ArLD. The results from the study will enable us to identify the factors influencing the drinking behaviour during lockdown and a subsequent impact on episodes of decompensation and mortality.


Clinical Trial Description

ICoLD, is a collaborative study between the King's College Hospital and SLaM. This is an observational self-report questionnaire study. The study population will comprise of people with alcohol-related chronic liver disease attending the Liver Outpatients and those admitted to the King's College Hospital. The study groups will be people who were abstinent of alcohol and people who have had history of alcohol consumption prior to lockdown. The study will ascertain drinking behaviour prior to lock down and during lock down/COVID restrictions. The study uses the Severity of Alcohol Dependence Questionnaire (SADQ) to ascertain the severity of physiological dependence and the Obsessive compulsive Drinking Scale (OCDS) to characterise craving. The SADQ, OCDS and detailed Alcohol history is usually collected as a standard of care in patients with AUD. The study will also investigate factors that could influence drinking behaviour during lockdown such as access to alcohol, affordability, pub closure/less socialising, boredom, time to reflect on health and psycho-social factors. Data on drinking behaviour, SADQ score and OCDS will be collected at any future lockdowns. Patients with ArLD will be identified from the Liver outpatients or approached during their Hospital admission. Approximately, 700 patients with ArLD are followed in the Liver outpatients. 200 patients will be enrolled during the lockdown period, considering drop outs and a proportion of patients not willing to participate in the study. The study population will be followed up for a year after the final lockdown/COVID restrictions are lifted. No statisticians were involved in planning this study as it is a pilot study to generate hypotheses regarding the drivers of changes in drinking in this population during lockdown. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04876443
Study type Observational
Source King's College Hospital NHS Trust
Contact Naina Shah, MBBS, MRCP (GIM), MRCP
Phone 02032999000
Email naina.shah1@nhs.net
Status Recruiting
Phase
Start date October 8, 2020
Completion date July 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Completed NCT02901041 - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism Phase 3
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Completed NCT02486900 - Neurofeedback & Alcohol Dependence N/A
Completed NCT02705898 - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02197598 - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Phase 4
Recruiting NCT02385643 - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients N/A
Completed NCT01828866 - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT01342549 - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Phase 3
Completed NCT02193204 - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk N/A
Completed NCT01176591 - HBPL Study of the Impact of the NK1 Antagonist Aprepitant Phase 2
Completed NCT01165541 - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency Phase 2
Completed NCT01056484 - Mindfulness Meditation for Health Phase 2
Completed NCT00585780 - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Phase 1/Phase 2
Completed NCT00607620 - Disseminating Organizational SBI Services at Trauma Centers N/A
Completed NCT00884884 - Aripiprazole and Topiramate on Free-Choice Alcohol Use Phase 2/Phase 3
Completed NCT00463346 - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Phase 3